Baxter 4Q Revenues: $4.4 billion (+16%) 4Q Earnings: $326 million (-34%) FY Revenues: $15.3 billion (+8%) FY Earnings: $2.0 billion (-13%) Comments: Excluding the contribution of Gambro revenues in the quarter, sales increased 5% to $4.0 billion. Sales in the U.S. totaled $1.8 billion (+13%), and international sales were $2.6 billion (+19%). BioScience revenues were $1.8 billion in the quarter, up 5%, driven by hemophilia therapies ADVATE and FEIBA in the U.S. and Europe, as well as biosurg...